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Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome
associated with life-threatening toxicity following exposure to the fluoropyrimidine drugs
5-fluorouracil (5-FU) and capecitabine (CAP), widely used for the treatment of colorectal
cancer and other solid tumors. The most prominent loss-of-function allele of the DPYD
gene is the splice-site mutation c.1905+1G>A. In this study we report the case of
a 73-year old woman with metastatic colorectal cancer who died from drug-induced
toxicity after the first cycle of 5-FU-containing chemotherapy. Her symptoms included
severe neutropenia, thrombocytopenia, mucositis and diarrhea; she died 16 days later
despite intensive care measures. Post-mortem genetic analysis revealed that the patient
was homozygous for the c.1905+1G>A deleterious allele and several family members
consented to being screened for this mutation. This is the first report in Spain of a
case of 5-FU-induced lethal toxicity associated with a genetic defect that results in the
complete loss of the DPD enzyme. Although the frequency of c.1905+1G>A carriers
in the white population ranges between 1 and 2%, the few data available for the
Spanish population and the severity of this case prompted us to design a genotyping
procedure to prevent future toxic effects of 5-FU/CAP. Since our group had previously
developed a high-resolution melting (HRM) assay for the simultaneous detection of
KRAS, BRAF, and/or EGFR somatic mutations in colorectal and lung cancer patients
considered for EGFR-targeted therapies, we included the DPYD c.1905+1G>A mutation
in the screening test that we describe herein. HRM provides a rapid, sensitive, and
inexpensive method that can be easily implemented in diagnostic settings for the routine
pre-therapeutic testing of a gene mutation panel with implications in the pharmacologic
treatment.
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INTRODUCTION
Dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2) is the ini-
tial rate-limiting step in the catabolism of endogenous pyrim-
idines, as well as in fluoropyrimidine drugs such as 5-fluorouracil
(5-FU) and its oral prodrug capecitabine (CAP), widely used
in the treatment of colorectal cancer and other solid tumors.
With a predominant expression in the liver, DPD rapidly cat-
alyzes the reduction of more than 80% of the 5-FU adminis-
tered (Heggie et al., 1987); thus, a reduced enzymatic activity
increases the half-life of the drug, resulting in excess accumu-
lation and toxicity (Ezzeldin and Diasio, 2004; Lee et al., 2004;
van Kuilenburg et al., 2008). DPD activity is highly variable
in the population, as it depends on many factors such as gen-
der, circadian rhythms, drug interactions and genetic polymor-
phisms (Mercier and Ciccolini, 2006); with an estimated 3–5%
of individuals experiencing low or deficient activity (Yen and
McLeod, 2007).
DPD deficiency (OMIM 274270) is an autosomal reces-
sive disorder described in pediatric patients presenting with
thymine-uraciluria and major symptoms of convulsion and
psychomotor retardation, although asymptomatic cases also
exist (Webster et al., 2001). A common trait in these patients
is the complete deficiency of DPD due to homozygosity or
compound heterozygosity of inactivating mutations in the
DPYD gene (van Kuilenburg et al., 1999). Likewise, the com-
plete or partial loss of DPD function in cancer patients
carrying DPYD mutant alleles is known to cause severe
life-threatening hematologic and gastrointestinal toxicity after
5-FU administration (Amstutz et al., 2011). Accounting for
50–75% of severe 5-FU-related toxicities (Ciccolini et al.,
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2010), DPD deficiency has been defined as a pharmacoge-
netic syndrome and is on the FDA’s list of approved biomark-
ers (http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/
Pharmacogenetics/ucm083378.htm). Lethal toxicities have been
reported in DPD deficient patients treated with either 5-FU
(Milano et al., 1999; Raida et al., 2001; van Kuilenburg et al.,
2001, 2003; Ezzeldin et al., 2003; Magné et al., 2007; Morel et al.,
2007; Saif et al., 2007a; Gross et al., 2008) or CAP (Ciccolini
et al., 2006; Largillier et al., 2006; Saif et al., 2007b; Deenen
et al., 2011). Indeed, combined pharmacogenetic syndromes with
a fatal outcome have been associated with concomitant muta-
tions in the DPYD and UTG1A1 genes (Steiner et al., 2005;
Mounier-Boutoille et al., 2010).
DPYD is a 843-kb, single copy gene located on chromosome
1p22 that comprises 23 exons and appears to be highly polymor-
phic, with more than 50 variants reported (Takai et al., 1994;
Yokota et al., 1994; Wei et al., 1998). However, only three individ-
ual variants have been consistently associated with 5-FU toxicity
in case-control studies (Amstutz et al., 2011): the two non-
synonymous substitutions c.1679T>G (I560S) and c.2846A>T
(D949V), which result in low enzyme activity but are very rare;
and c.1905+1G>A (formerly IVS14+1G>A or DPYD∗2A), a
point mutation in the splice donor site that results in a 165-bp
deletion in the mRNA, due to skipping of exon 14, and lack of
functional DPD expression (Meinsma et al., 1995; Vreken et al.,
1996; Wei et al., 1996).
The c.1905+1G>A mutation has been the most frequently
studied in the context of 5-FU toxicity as it proved to be the
most prevalent among patients with complete DPD deficiency
(52%) (van Kuilenburg et al., 1999) and was detected in 24%
of cancer patients suffering grade 4 leucopenia, with the major-
ity of them being heterozygous (Raida et al., 2001). Moreover,
large general population screenings for the c.1905+1G>A muta-
tion showed 1–2% of heterozygous carriers (Raida et al., 2001;
van Kuilenburg et al., 2001), rendering this allele attractive for
routine mutation screening. However, subsequent studies indi-
cated a north-south gradient in Europe, so the proportion of
5-FU toxicity cases explained by the c.1905+1G>A variant var-
ied greatly due to population frequency differences and sampling
effects (Amstutz et al., 2011).
In Spain, the only studies addressing the prevalence of this
mutation were conducted in colorectal cancer patients treated
with 5-FU (Paré et al., 2010) and CAP (Salgado et al., 2007),
showing heterozygote frequencies of 0% (0/234) and 1.7% (1/58),
respectively. Some cases of 5-FU/CAP-induced severe toxicity
in DPD-deficient patients have been reported in our country,
mainly via communications at congresses or in pharmacy jour-
nals (Gironés Sarrió et al., 2005; López Sobella et al., 2008; Rubio
Salvador et al., 2012). In the most recent report, and the only
study to perform a genetic analysis, one toxic death was attributed
to heterozygosity of an unspecified mutant DPYD allele (Rubio
Salvador et al., 2012). It is also worth mentioning the case of a
Spanish woman, reported in a French study, who died from 5-FU
toxicity due to heterozygosity for the c.464T>A mutation (Morel
et al., 2007).
The relatively high frequency of the c.1905+1G>A variant,
with 1.3% of heterozygote carriers according to 1000 Genomes
data (rs3918290 polymorphism in 1000GENOMES:EUR pop-
ulation at http://browser.1000genomes.org), together with the
widespread use of 5-FU/CAP and the severity of the associated
toxicities, prompted us to develop a fast and reliable method to
identify high-risk individuals prior to undergoing pyrimidine-
based chemotherapy. Since we had previously developed a
high-resolution melting (HRM) assay to detect somatic KRAS,
BRAF, and EGFR mutations in tumor samples from patients
considered for EGFR-targeted therapies (Borràs et al., 2011), we
included the detection of the DPYD c.1905+1G>A mutation in
this screening test.
The HRM method is based on a PCR amplification using a
saturating intercalating dye, followed by DNA strand separation
in a temperature gradient, during which the fluorescence is regis-
tered with a high resolution. Thus, the melting curves obtained
for homozygous and heterozygous samples differ significantly.
Likewise, for somatic mutations, the presence of mutated alleles
results in abnormal melting profiles.
Herein, we report the first case in Spain of a patient
with 5-FU-induced lethal toxicity due to homozygosity for the
c.1905+1G>A mutation, and describe a HRM assay for the
routine testing of cancer patients prior to 5-FU/CAP therapy.
MATERIALS AND METHODS
DNA SAMPLES
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the internal Clinical Research
Ethics Committee (CEIC) of the Hospital de Terrassa (Spain).
Informed consent was obtained from all the participants
and has been archived by the authors. Genomic DNA sam-
ples were obtained from a patient who died from 5-FU-
induced toxicity and her close relatives. In the case of the
index patient, the DNA was extracted from stored frozen
blood samples and the consent for genotyping was pro-
vided by the relatives after the patient’s death. DNA isolation
from peripheral blood lymphocytes was performed automati-
cally by the MagNaPure Compact Instrument (Roche Applied
Science, Barcelona, Spain) according to the manufacturer’s
protocol.
PCR AMPLIFICATION AND SEQUENCING
A newly designed forward primer (5′-TATGGCCCTGGACAAA
GCTC-3′) was combined with an existing reverse primer for
DPYD exon 14 (5′-CAGCAAAGCAACTGGCAGATT-3′) (Kumar
et al., 2007) to generate a 239-bp amplicon. Primer specificity and
melting temperatures were analyzed using Primer-BLAST soft-
ware (http://www.ncbi.nlm.nih.gov/tools/primer-blast). PCR
amplification was conducted in a 50µl final volume containing:
1x PCR buffer, 1.5mM MgCl2, 500 nM primers, 2µl genomic
DNA (32 ng to 1.7µg), 200µM dNTPs, 2.5U of BioTaq poly-
merase (Bioline, Ecogen, Barcelona, Spain), and PCR grade
water. The program conditions were: 5min at 95◦C followed
by 35 cycles of 30 s at 95◦C, 30 s at 56.6◦C and 1min at 72◦C.
PCR products were analyzed by 1.5% agarose gel electrophoresis,
column purified with the High Pure PCR Product Purification
Kit (Roche) and submitted to StabVida (Oeiras, Portugal) for
direct sequencing on a 3730XL ABI DNA sequencer (Applied
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Biosystems, Foster City, CA) using the Big Dye terminator V1.1
DNA sequencing kit.
DESIGN OF HRM PRIMERS
First, the primers used for PCR amplification were tested to
ensure good genotype discrimination in a LightCycler® 480
platform (Roche) using the previously described HRM assay
(Borràs et al., 2011). After optimization of the touchdown PCR
annealing temperature range, the DNA samples were successfully
amplified and heterozygous carriers of the c.1905+1G>A muta-
tion could be easily identified. However, the melting profiles of
mutant and wild-type homozygous samples were almost identi-
cal. Alternative primers were designed in order to obtain shorter
amplicons, in which a nucleotide change would have a greater
effect on the curve shape, with a single melting domain and a low
level of secondary structure, according to Stitchprofiles.uio.no
(http://stitchprofiles.uio.no) and DINAMelt Web Server (http://
mfold.rna.albany.edu/?q=DINAMelt) predictions, but the ini-
tial results could not be improved. We therefore decided to use
the above mentioned primers but to spike all samples with a
known amount of wild-type DNA from a control individual to
ensure differentiation of homozygous variants, as suggested in
LightCycler® 480 Technical Note No. 1 (2008).
HRM ASSAY
Samples were diluted at the same concentration and spiked
with 0.5 volumes of wild-type DNA, so the mutant:wild-type
allele ratio (2:1 in mutant homozygous, 1:2 in heterozygous,
and 0:3 in wild-type samples) maximized the ability to discrim-
inate genotypes. Test samples were assayed in triplicate using
the LightCycler® 480 system, and negative (non-template) and
wild-type controls were included in each experiment. Each 10-µl
reaction contained about 30 ng DNA diluted in 1.8µl, 1x HRM
mix (Roche), 3mM MgCl2, and 200 nM HPLC-purified primers.
Touchdown PCR and melting conditions were: 95◦C for 10min;
45 cycles of 95◦C for 10 s, 60-53◦C (1◦C/cycle) for 15 s and 72◦C
for 10 s; 95◦C for 1min; 40◦C for 1min; a melt of 72-92◦C
(0.01◦C/s, 45 acquisitions/◦C); and 40◦C for 10 s. Normalized and
temperature-adjusted melting curves of test samples and wild-
type controls were visualized with accompanying Gene Scanning
software. Since Standards (In Run) analysis mode (grouping
method) was selected, the software assigned each sample to a
group based on melting standard samples included in the run
(wild-type replicates). Amplicons displaying abnormal melting
patterns as compared to wild-type samples could be recovered
from the plate, column purified and subjected to direct sequenc-
ing as described above.
RESULTS
CLINICAL EVALUATION
The index patient was female, born in 1937, and had a history of
allergic rhinitis, adenoid surgery, 2 vaginal childbirths, and hys-
terectomy due to uterine prolapse. In 2007, she consulted for con-
stipation with some degree of urinary and fecal incontinence and
was diagnosed with rectocele and rectal prolapse. One year later,
a large and sessile serrated adenoma of the rectum was detected
and the patient underwent transanal endoscopic microsurgery.
The pathological examination of the surgical specimen revealed
an infiltrating adenocarcinoma (T1) and colonoscopic follow-up
was scheduled. After 17 months, she was found to have neo-
plastic recurrence (T3p N1) with multiple liver metastases and
was considered for palliative chemotherapy with mFOLFOX6.
At that time, she was slightly overweight (BMI of 29.2 kg/m2:
weight 64 kg, height 148 cm) without other cardiovascular risk
factors, such as smoking or hypertension and showed normal liver
and renal function. The first cycle, administered on January 12,
2010, involved a 2-h infusion (i.v.) of oxaliplatin (85mg/m2) and
leucovorin (200mg/m2), followed by administration of a 5-FU
bolus (400mg/m2 i.v.) and 48-h continuous infusion of 5-FU
(2400mg/m2 i.v.) using a portable pump.
On day 6 of this treatment, the patient presented to the
emergency department after 3–4 days of vomiting and diarrhea,
intolerance to liquids and solids, and general malaise without
fever or abdominal pain, despite having taken the prescribed
ondansetron. After receiving symptomatic medication consisting
of pantoprazole, metoclopramide, paracetamol, and serum ther-
apy, she remained hemodynamically stable and was admitted to
the oncology service diagnosed with grade 3 mucositis. Despite
a moderate initial improvement, the oral mucositis persisted
and worsened to grade 4. Over the next few days, fluconazole
treatment and morphine (s.c.) analgesia were given, and total
parenteral nutrition was instituted. Prophylactic filgastrim and
ciprofloxacin were given due to the severity of the mucositis
and the presence of afebrile grade 3 neutropenia (0.58 × 109/l),
though the development of grade 4 thrombocytopenia required
platelet transfusion. Of note, the diarrhea persisted during the
entire admission period. After the appearance of fever and grade 4
neutropenia (0.02 × 109/l), the antibiotic coverage was extended
to piperacillin/tazobactam, but the patient developed septic shock
and vasoactive drugs had to be perfused. Despite all the measures
taken, the patient progressed poorly and died on January 28, 16
days after the first 5-FU dose.
SEQUENCE ANALYSIS OF THE DPYD GENE
Direct sequencing of the 239-bp amplicon containing the DPYD
exon 14 coding and flanking intron region revealed that the
index patient was homozygous for the c.1905+1G>A mutation
(II.2 in Figures 1, 2). Although no functional test could be per-
formed due to unavailability of fresh blood samples, DPD activity
was assumed to be completely absent according to a prior study
describing the fatal outcome of a c.1905+1G>A homozygous
patient with no significant residual activity of DPD in peripheral
blood mononuclear cells and fibroblasts (van Kuilenburg et al.,
2001).
The family study by PCR amplification followed by direct
sequencing confirmed that both sons of the index patient were
obligate heterozygotes (III.2 and III.3 in Figures 1, 2) and the
only sister analyzed was wild type (II.5 in Figures 1, 2). Of note,
none of the mutation carriers of this family presented symptoms
of familial pyridinemia and DPD deficiency was not discovered
until the administration of 5-FU. To date, none of the other sib-
lings of the index patient are available for testing. Nevertheless,
as the members studied represent the three genotypes, their DNA
samples were used to evaluate the validity of the HRM assay.
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FIGURE 1 | Pedigree of the index patient and family members carrying
the DPYD c.1905+1G>A mutation. The index patient is indicated by an
arrow. For family members who were alive, age at the time of the study is
shown below in italics. For deceased members, designated by a diagonal line
through the symbol, age and cause of death are annotated (CRC, colorectal
cancer; AMI, acute myocardial infarction). Numbers inside a diamond are
children of unspecified sex. DPYD genotypes are wild type (−/−),
heterozygous (+/−) and homozygous (+/+) carriers of the mutation.
HRM ANALYSIS OF THE DPYD c.1905+1G>A MUTATION
The HRM assay developed was tested using triplicates of the
above mentioned samples, adjusted to the same concentration
and spiked with wild-type DNA. The homozygous mutant
sample showed the lowest DNA concentration (16 ng/µl) as a
result of the severe neutropenia, so the other samples were
diluted accordingly. Homozygous and heterozygous carriers of
the DPYD c.1905+1G>A mutation were successfully identi-
fied by HRM analysis, either using the adjusted melting curves
(Figure 3A) or the differential plot (Figure 3B). The adjusted
melting curves show a single melting domain, consistent with
Stitchprofiles.uio.no predictions, but, since the melting curves
of mutation carriers are a composite of both heteroduplex and
homoduplex components, they dissociate more readily and shift
left to a lower temperature. The difference plot calculation
assigned the samples in two groups using sensitivity values from
0.2 (higher values denote high stringency and produce more
groups), so the mutant samples (either homozygous or het-
erozygous) were distinguished from the wild-type ones (melting
standards). For good HRM analysis, amplification curves were
checked to produce a crossing point <30 and to reach a similar
plateau height and, if replicates showed different melting patterns,
the assay was repeated for that sample. Finally, the touchdown
PCR and melting conditions of this DPYD HRM assay were suit-
able for analysis of KRAS, BRAF, and EGFR somatic hotspot
mutations in tumor samples (not shown), thus enabling simulta-
neous analysis of relevant mutations for targeted cancer therapy.
DISCUSSION
To date, screening for the presence of DPD deficiency prior to
5-FU chemotherapy is not yet established in the daily care of
cancer patients, despite the numerous studies worldwide report-
ing life-threatening toxicity cases. Therefore, while not specified
in professional guidelines, there is general consensus that given
the large number of patients treated with 5-FU and the human
and economic cost of grade 3–4 toxic side effects, DPD deficiency
should be tested for prior to initiation of therapy.
Several methods have been developed to assess DPD activ-
ity, such as direct assays in peripheral blood mononuclear
cells, indirect evaluations by monitoring DPD substrates or
metabolites (e.g., uracil/dihydrouracil plasma ratio, uracil breath
test), administration of a 5-FU test dose, and measurement of
DPD expression through mRNA or protein levels (Mercier and
Ciccolini, 2006; Eidens et al., 2009). However, functional tests
usually require special equipment and are too costly and labo-
rious for routine implementation in clinical practice. In contrast,
genotyping methods are available in most laboratories but offer
an incomplete pharmacogenetic diagnosis because of the limited
number of genetic variants tested and the lack of a straight-
forward genotype-phenotype correlation. Combining the two
approaches may provide the most complete assessment of toxicity
risk, although no guidelines currently exist specifying a particular
testing method.
Regarding genotyping, comprehensive genetic screenings
including the variation in noncoding regions result in a higher
relative importance of DPYD variants to explain 5-FU toxicities.
Current data suggest that combining information from multiple
variants in this gene can identify over 20% of patients expe-
riencing severe 5-FU toxicity (Amstutz et al., 2011). On the
other hand, heterozygous carriers of deleterious variants can show
normal DPD activity and only about 50% of carriers develop
severe 5-FU toxicity, which suggests an allelic regulation through
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FIGURE 2 | Sequence chromatograms of the index patient and family
members analyzed for the DPYD c.1905+1G>A mutation. Trace
sequences of DPYD exon 14 coding and flanking intron region including
position c.1905 (indicated with an arrow). From top to bottom:
c.1905+1G>A homozygous (index patient, II.2), heterozygous (sons, III.2
and III.3), and wild type (sister, II.5).
an increased expression of the wild-type allele or compensa-
tion by another variant that confers above-average DPD activity
(Amstutz et al., 2011). Whatever the case, extensive analyses
of DPYD could address this issue. Moreover, genotype testing
could be expanded to genetic variants in genes that may play a
role in 5-FU breakdown, such as thymidilate synthase (TYMS)
and methylenetetrahydrofolate reductase (MTHFR), which could
modulate the impact of DPYD risk alleles on the overall risk of
toxicity.
High-throughput sequencing technologies promise to sub-
stantially simplify this task in the future, as full sequencing of
DPYD and other genes of potential importance for 5-FU toxic-
ity will be achieved at reasonable costs. Further comprehensive
genetic screenings in combination with phenotypic character-
ization of DPYD genotypes could help to identify the factors
underlying the occurrence of normal DPD activity in carriers of
risk alleles and to discern the relative contribution of individ-
ual DPYD variants. Meanwhile, methodologies based on genetic
testing for clinically relevant variants offer the simplest way to
identify patients at the highest risk of potentially life-threatening
adverse drug events.
In this context, we describe an approach to detect the
c.1905+1G>A mutation of DPYD based on HRM technology,
which shows great potential for scanning germline and somatic
mutations (Taylor, 2009). A HRM assay previously designed by
our group (Borràs et al., 2011) had already successfully identi-
fied hotspot mutations of KRAS, BRAF, and EGFR with a high
analytical sensitivity. Moreover, the use of a touchdown PCR
and a wide melting interval allowed the simultaneous analy-
sis of all amplicons in a single plate, saving time and cost.
Although this assay was developed for FFPE tumor sections, it
is also suitable for blood samples, and both DNA sources can
be combined in one experiment to detect somatic and germline
mutations. As DNA isolation from blood samples usually gives
higher yields and better quality, lower amounts of template
could be used, but the amount of starting DNA has to be stan-
dardized as much as possible to minimize reaction-to-reaction
variability.
Since this test has to be validated before it is used in routine,
we plan to conduct a pilot study in our institution to genotype the
DPYD c.1905+1G>A mutation in cancer patients and to assess
its importance in 5-FU toxicity. Considering that 5-FU is widely
prescribed for the treatment of solid carcinomas, like those of
the gastrointestinal tract, pretreatment DPYD genotyping could
be performed together with the detection of KRAS and BRAF
somatic mutations in patients with colorectal cancer to predict
the response to anti-EGFRmonoclonal antibodies, recommended
by regulatory authorities (van Krieken et al., 2008; Allegra et al.,
2009; NCCN Colon Cancer Guidelines, 2011).
Just as better mutation detection methods are required for
stratification of patients to receive molecularly targeted treat-
ment, tests are needed for the cost-effective screening of genes
associated with drug metabolism and response. Understanding
pharmacogenetic associations is especially important in cancer
chemotherapy, as many chemotherapeutic agents, such as 5-
FU, have a very narrow therapeutic index. Among the various
techniques available to detect DPD deficiency at genotype level,
including many marketed tests, HRM analysis provides a rapid,
sensitive, and inexpensive method that can be easily implemented
in a diagnostic setting.
HRM has been applied to mutation scanning of the cytidine
deaminase gene (CDA), involved in the catabolism of nucleoside
analogs, genetic variations of which might explain the therapeu-
tic and toxic response to gemcitabine (Evrard et al., 2007a,b).
Specifically, the LightCycler® 480 platform was used to investi-
gate variations in long PCR fragments and to genotype SNPs
or mutations in short amplicons, and HRM efficiently identi-
fied single base heterozygous changes in PCR products up to 622
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FIGURE 3 | HRM analysis of the DPYD c.1905+1G>A mutation in
a 239-bp amplicon. Normalized and temperature-shift melting curves
(A) and differential plot (B) of mutant homozygous (II.2, blue),
heterozygous (III.2, red), and wild-type (II.5, green) samples, assayed
in triplicate. As all samples were spiked with wild-type DNA,
homozygous and heterozygous mutants show similar left-shifted
melting curves and can be easily identified, especially in the
differential plot.
bp. However, differentiation of homozygous variants depended
on amplicon length and GC content, so the use of modified
DNA is suggested. Spikes of wild-type DNA added to all sam-
ples and comparison to unspiked reactions has been shown by
others to provide a valuable approach to addressing this point.
Furthermore, the authors compare three methods for routine
detection of c.1905+1G>A mutation in the DPYD and consider
HRM to be a powerful tool for genotyping known SNPs or muta-
tions in routine clinical practice (Evrard et al., 2007a,b). However,
just like any screening test, HRM-identified positive samples have
to be subsequently sequenced to identify the specific nucleotide
alteration, which may be present in one or both alleles, and to
avoid misdiagnosis due to an abnormal curve generated by a
neutral variant.
An important limitation of our study is that screening for the
c.1905+1G>A mutation alone may have limited effectiveness in
identifying patients at risk of lethal 5-FU toxicity and could result
in false-negative results for patients with rare DPYD variants or
who might experience severe toxicity as a result of other causes.
Prospective analysis of the c.1905+1G>Amutation in large num-
bers of toxicity cases and controls from our population is needed
for a reliable estimation of the importance of this variant for the
prediction of 5-FU toxicity in cancer patients and to determine
the cost-effectiveness of a genetic strategy for DPD screening.
In this study, we describe the case of a woman with an unre-
markablemedical history before the diagnosis of colorectal cancer
followed by surgery and 5-FU-based chemotherapy, with subse-
quent unexpected gastrointestinal and hematologic toxicity lead-
ing to death. As in other reports, most patients have no symptoms
of DPD deficiency and are unaware of their condition prior to
5-FU treatment and the subsequent development of adverse side
effects. In contrast, both sons of the index patient are known to
be heterozygous carriers of the c.1905+1G>A mutation but the
clinical implications of partial DPD deficiency are unpredictable
since not everybody who carries the risk allele may actually suffer
severe 5-FU side effects. In these cases, determination of the
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5-FU pharmacokinetics could aid individualized therapy since the
application of dose-tailored strategies based on pharmacokinetic
monitoring improved the therapeutic index of 5-FU treatment,
and it could be used in conjunction with genotyping to reduce
toxicity and achieve maximum benefit (Saif et al., 2009; Yang
et al., 2011).
As a standard practice, many authors have suggested that
patients with decreased DPD activity should be monitored
closely, considered for a reduced 5-FU dose, or chosen for an
alternative therapy (Raida et al., 2001; Lazar and Jetter, 2008;
Ciccolini et al., 2010). More recently, the Pharmacogenomics
Working Group of the Royal Dutch Association for the
Advancement of Pharmacy established clinical guidelines for
5-FU therapy according to DPYD genotype, available at the
Pharmacogenomics Knowledge Base (www.pharmgkb.org). For
patients carrying two inactive or decreased activity alleles, they
recommend selecting an alternative drug, whereas for patients
with one active and one inactive or decreased activity allele, a 50%
dose reduction or selection of another drug is recommended.
With the aim of contributing toward the implementation of
a pre-screening program for DPD deficiency and helping to
improve the safety of 5-FU-based chemotherapy, we have devel-
oped a HRM assay for the screening of DPYD c.1905+1G>A
mutation. This method provides a simple, robust, and inexpen-
sive solution that can be easily implemented in diagnostic settings
for pre-therapy testing. Therefore, after proper validation for rou-
tine use, we plan to include the present test in a panel of other tests
for somatic cancer mutations with implication on the selection of
therapy.
ACKNOWLEDGMENTS
We thank Ian Johnstone for the English language revision and
editing of the manuscript. We are also grateful to Dr. Gemma
Llort and Carmen Yagüe, from the Genetic Counseling Unit
(Institut Oncològic del Vallès, Hospital de Terrassa), for recruit-
ing the members of the family studied and providing the genetic
pedigree. This work was supported by grants from Spanish Health
Ministry (FIS) network RIRAAF (RD 07/0064).
REFERENCES
Allegra, C. J., Jessup, J. M., Somerfield,
M. R., Hamilton, S. R., Hammond,
E. H., Hayes, D. F., et al. (2009).
American Society of Clinical
Oncology provisional clini-
cal opinion: testing for KRAS
gene mutations in patients with
metastatic colorectal carcinoma to
predict response to anti-epidermal
growth factor receptor monoclonal
antibody therapy. J. Clin. Oncol. 27,
2091–2096.
Amstutz, U., Froehlich, T. K.,
and Largiader, C. R. (2011).
Dihydropyrimidine dehydroge-
nase gene as a major predictor
of severe 5-fluorouracil toxicity.
Pharmacogenomics 12, 1321–1336.
Borràs, E., Jurado, I., Hernan, I.,
Gamundi, M. J., Dias, M., Martí,
I., et al. (2011). Clinical pharma-
cogenomic testing of KRAS, BRAF
and EGFR mutations by high res-
olution melting analysis and ultra-
deep pyrosequencing. BMC Cancer
11:406. doi: 10.1186/1471-2407-11-
406
Ciccolini, J., Gross, E., Dahan, L.,
Lacarelle, B., andMercier, C. (2010).
Routine dihydropyrimidine dehy-
drogenase testing for anticipating
5-fluorouracil-related severe toxici-
ties: hype or hope? Clin. Colorectal
Cancer 9, 224–228.
Ciccolini, J., Mercier, C., Dahan, L.,
Evrard, A., Boyer, J. C., Richard,
K., et al. (2006). Toxic death-case
after capecitabine + oxaliplatin
(XELOX) administration: probable
implication of dihydropyrimi-
dine dehydrogenase deficiency.
Cancer Chemother. Pharmacol. 58,
272–275.
Deenen, M. J., Tol, J., Burylo, A.
M., Doodeman, V. D., de Boer,
A., Vincent, A., et al. (2011).
Relationship between single
nucleotide polymorhisms and hap-
lotypes in DPYD and toxicity and
efficacy of capecitabine in advanced
colorectal cancer. Clin. Cancer Res.
17, 3455–3468.
Eidens, M., Prause, S., Weise,
A., Klemm, M., Weber, M.
W., and Pfutzner, A. (2009).
Dihydropyrimidine dehydrogenase
genotyping and phenotyping for
5-fluorouracil dysmetabolism:
moving towards personalized
chemotherapy in patients with
cancer. Curr. Pharmacogenomics
Person. Med. 7, 275–283.
Evrard, A., Raynal, C., Boyer, J. C.,
le Gallic, L., and Lumbroso, S.
(2007a). Mutation scanning of the
cytidine deaminase gene by high-
resolution melting curve analysis
using the LightCycler® 480 system.
Biochemica 3, 13–14.
Evrard, A., Raynal, C., Ciccolini, J.,
Mercier, C., le Gallic, L., Polge,
A., et al. (2007b). “Mutation scan-
ning of the cytidine deaminase
(CDA) and dihydropyrimidine
dehydrogenase (DPYD) genes by
high-resolution melting curve
analysis in cancer patients treated
with antimetabolites drugs,”
in P-029, HUGO’s HGM 2007
Congress. Available online at:
http://www.roche-applied-science.
com/sis/rtpcr/htc/htc_docs/posterh
rm_2007_a4.pdf
Ezzeldin, H., and Diasio, R. (2004).
Dihydropyrimidine dehydrogenase
deficiency, a pharmacogenetic syn-
drome associated with potentially
life-threatening toxicity following
5-fluorouracil administration. Clin.
Colorectal Cancer 4, 181–189.
Ezzeldin, H., Johnson, M. R., Okamoto,
Y., and Diasio, R. B. (2003).
Denaturing high performance
liquid chromatography analysis of
the DPYD gene in patients with
lethal 5-fluorouracil toxicity. Clin.
Cancer Res. 9, 3021–3028.
Gironés Sarrió, R., Wolstein Lara,
C., and Torregrosa Maicas, M. D.
(2005). Déficit de dihidropirimid-
ina deshidrogenasa (DPD): ¿pen-
samos en él? Clin. Transl. Oncol.
7(Suppl.1), 151 (L-46, SEOM 2005
Congress).
Gross, E., Busse, B., Riemenschneider,
M., Neubauer, S., Seck, K.,
Klein, H. G., et al. (2008).
Strong association of a common
dihydropyrimidine dehydroge-
nase gene polymorphism with
fluoropyrimidine-related toxicity in
cancer patients. PLoS ONE 3:e4003.
doi: 10.1371/journal.pone.0004003
Heggie, G. D., Sommadossi, J. P., Cross,
D. S., Huster, W. J., and Diasio, R. B.
(1987). Clinical pharmacokinetics
of 5-fluorouracil and its metabolites
in plasma, urine, and bile. Cancer
Res. 47, 2203–2206.
Kumar, C. K., Murthy, S., and Jamil,
K. (2007). Possible associations
of splice site mutation of dihy-
dropyrimidine dehydrogenase
(IVS14+1G>A) in adverse drug
reactions in some invasive duc-
tal carcinoma patients. Int. J.
Pharmacol. 3, 130–136.
Largillier, R., Etienne-Grimaldi, M.
C., Formento, J. L., Ciccolini, J.,
Nebbial, J. F., Ginot, A., et al.
(2006). Pharmacogenetics of
capecitabine in advanced breast
cancer patients. Clin. Cancer Res. 12,
5496–5502.
Lazar, A., and Jetter, A. (2008).
Pharmacogenetics in oncology:
5-fluorouracil and the dihydropy-
rimidine dehydrogenase. Dtsch.
Med. Wochenschr. 133, 1501–1504.
Lee, A., Ezzeldin, H., Fourie,
J., and Diasio, R. (2004).
Dihydropyrimidine dehydro-
genase deficiency: impact of
pharmacogenetics on 5-fluorouracil
therapy. Clin. Adv. Hematol. Oncol.
2, 527–532.
LightCycler® 480 Technical Note No.
1. (2008). High Resolution Melting:
Optimization Strategies. Available
online at: http://www.gene-
quantification.de/LC480-Technical-
Note-01-HRM.pdf
López Sobella, M., Criado Illana,
M. T., Esteban Herrera, B., and
López Arranz, M. C. (2008). Severe
5-fluorouracil induced toxicity
associated with dihydropyrimidine
dehydrogenase deficiency dehydro-
genase deficiency. Farm. Hosp. 32,
54–56.
Magné, N., Etienne-Grimaldi, M. C.,
Cals, L., Renée, N., Formento, J.
L., Francoual, M., et al. (2007).
Dihydropyrimidine dehydrogenase
activity and the IVS14+1G>A
mutation in patients developing
5FU-related toxicity. Br. J. Clin.
Pharmacol. 64, 237–240.
Meinsma, R., Fernandez-Salguero, P.,
van Kuilenburg, A. B. P., van
Gennip, A. H., and Gonzalez, F.
J. (1995). Human polymorphism
in drug metabolism: mutation in
the dihydropyrimidine dehydroge-
nase gene results in exon skipping
www.frontiersin.org January 2013 | Volume 3 | Article 312 | 7
Borràs et al. DPD mutation detection by HRM
and thymine uraciluria. DNA Cell
Biol. 14, 1–6.
Mercier, C., and Ciccolini, J. (2006).
Profiling dihydropyrimidine
dehydrogenase deficiency in
patients with cancer undergoing
5-fluorouracil/capecitabine therapy.
Clin. Colorectal Cancer 6, 288–296.
Milano, G., Etienne, M. C., Pierrefite,
V., Barberi-Heyob, M., Deporte-
Fety, R., and Renee, N. (1999).
Dihydropyrimidine dehydrogenase
deficiency and fluorouracil-related
toxicity. Br. J. Cancer 79, 627–630.
Morel, A., Boisdron-Celle, M., Fey, L.,
Lainé-Cessac, P., and Gamelin, E.
(2007). Identification of a novel
mutation in the dihydropyrimidine
dehydrogenase gene in a patient
with a lethal outcome following 5-
fluorouracil administration and the
determination of its frequency in a
population of 500 patients with col-
orectal carcinoma. Clin. Biochem.
40, 11–17.
Mounier-Boutoille, H., Boisdron-Celle,
M., Cauchin, E., Galmiche, J. P.,
Morel, A., Gamelin, E., et al. (2010).
Lethal outcome of 5-fluorouracil
infusion in a patient with a total
DPD deficiency and a double DPYD
and UTG1A1 gene mutation. Br. J.
Clin. Pharmacol. 70, 280–283.
NCCN Clinical Practice Guidelines in
Oncology. (2011). Colon Cancer.
v.1.2011. Available online
at: http://www.nccn.org/pro-
fessionals/physician_gls/PDF/
colon.pdf
Paré, L., Páez, D., Salazar, J., del
Río, E., Tizzano, E., Marcuello, E.,
et al. (2010). Absence of large intra-
genic rearrangements in the DPYD
gene in a large cohort of colorec-
tal cancer patients treated with 5-
FU-based chemotherapy. Br. J. Clin.
Pharmacol. 70, 268–272.
Raida, M., Schwabe, W., Häusler, P., van
Kuilenburg, A. B. P., van Gennip,
A. H., Behnke, D., et al. (2001).
Prevalence of a common point
mutation in the dihydropyrimi-
dine dehydrogenase (DPD) gene
within the 5′-splice donor site of
intron 14 in patients with severe 5-
fluorouracil (5-FU)-related toxicity
compared to controls. Clin. Cancer
Res. 7, 2832–2839.
Rubio Salvador, A. R., Chacón López-
Muñiz, J. I., López Gómez, L. J.,
Medina Martínez, J., Martínez
Sesmero, J. M., Moya Gómez, P.,
et al. (2012). Toxic death-case
after capecitabine administration:
case report and implication of
dihydropyrimidine dehydrogenase
deficiency. Eur. J. Hosp. Pharm.
19, 132 (GRP125, EAHP 2012
Congress).
Saif, M. W., Choma, A., Salamone,
S. J., and Chu, E. (2009).
Pharmacokinetically guided dose
adjustment of 5-fluorouracil: a
rational approach to improving
therapeutic outcomes. J. Natl.
Cancer Inst. 101, 1–10.
Saif, M. W., Ezzeldin, H., Vance,
K., Sellers, S., and Diasio, R. B.
(2007a). DPYD*2A mutation: the
most common mutation associ-
ated with DPD deficiency. Cancer
Chemother. Pharmacol. 60, 503–507.
Saif, M. W., Syrigos, K., Mehra, R.,
Mattison, L. K., and Diasio, R. B.
(2007b). Dihydropyrimidine dehy-
drogenase deficiency (DPD) in gas-
trointestinal malignancies: experi-
ence of 4-years. Pak. J. Med. Sci. Q.
23, 832–839.
Salgado, J., Zabalegui, N., Gil,
C., Monreal, I., Rodríguez, I.,
and García-Foncillas, J. (2007).
Polymorphisms in the thymidylate
synthase and dihydropyrim-
idine dehydrogenase genes
predict response and toxicity to
capecitabine-raltitrexed in col-
orectal cancer. Oncol. Rep. 17,
325–328.
Steiner, M., Seule,M., Steiner, B., Bauer,
I., Freund, M., Köhne, C. H., et al.
(2005). 5-Fluorouracil/irinotecan
induced lethal toxicity as a result
of a combined pharmacogenetic
syndrome: report of a case. J. Clin.
Pathol. 58, 553–555.
Takai, S., Fernandez-Salguero, P.,
Kimura, S., Gonzalez, F. J., and
Yamada, K. (1994). Assignment
of the human dihydropyrimidine
dehydrogenase gene (DPYD) to
chromosome region 1p22 by flu-
orescence in situ hybridization.
Genomics 24, 613–614.
Taylor, C. F. (2009). Mutation scan-
ning using high-resolution melting.
Biochem. Soc. Trans. 37, 433–437.
van Krieken, J. H., Jung, A., Kirchner,
T., Carneiro, F., Seruca, R., Bosman,
F. T., et al. (2008). KRAS mutation
testing for predicting response
to anti-EGFR therapy for col-
orectal carcinoma: proposal for
a European quality assurance
program. Virchows Arch. 453,
417–431.
van Kuilenburg, A. B. P., Baars, J.
W., Meinsma, R., and van Gennip,
A. H. (2003). Lethal 5-fluorouracil
toxicity associated with a novel
mutation in the dihydropyrimidine
dehydrogenase gene.Ann.Oncol. 14,
341–342.
van Kuilenburg, A. B. P., Maring, J.
G., Schalhorn, A., Terborg, C.,
Schmalenberg, H., Behnke, D.,
et al. (2008). Pharmacokinetics
of 5-fluorouracil in patients het-
erozygous for the IVS14+1G > A
mutation in the dihydropyrimidine
dehydrogenase gene. Nucleosides
Nucleotides Nucleic Acids 27,
692–698.
van Kuilenburg, A. B. P., Muller,
E. W., Haasjes, J., Meinsma, R.,
Zoetekouw, L., Waterham, H. R.,
et al. (2001). Dihydropyrimidinase
lethal outcome of a patient with
a complete dihydropyrimidine
dehydrogenase (DPD) defi-
ciency after administration of
5-fluorouracil: frequency of the
common IVS14+1G>A mutation
causing DPD deficiency. Clin.
Cancer Res. 7, 1149–1153.
van Kuilenburg, A. B. P., Vreken, P.,
Abeling, N. G. G. M., Bakker, H.
D., Meinsma, R., van Lenthe, H.,
et al. (1999). Genotype and phe-
notype in patients with dihydropy-
rimidine dehydrogenase deficiency.
Hum. Genet. 104, 1–9.
Vreken, P., van Kuilenburg, A. B. P.,
Meinsma, R., Smit, G. P., Bakker,
H. D., de Abreu, R. A., et al.
(1996). A point mutation in an
invariant splice donor site leads
to exon skipping in two unre-
lated Dutch patients with dihy-
dropyrimidine dehydrogenase defi-
ciency. J. Inherit. Metab. Dis. 19,
645–654.
Webster, D. R., Becrof, D. M. O., van
Gennip, A. H., and van Kuilenburg,
A. B. P. (2001). “Hereditary orotic
aciduria and other disorders of
pyrimidine metabolism,” in The
Metabolic and Molecular Bases of
Inherited Disease, 8th Edn, eds C. R.
Scriver, A. L. Beaudet, W. S. Sly, and
D. Valle (New York, NY: McGraw-
Hill), 2663–2702.
Wei, X., Elizondo, G., Sapone, A.,
McLeod, H. L., Raunio, H.,
Fernandez-Salguero, P., et al.
(1998). Characterization of the
human dihydropyrimidine dehy-
drogenase gene. Genomics 51,
391–400.
Wei, X., McLeod, H. L., McMurrough,
J., Gonzalez, F. J., and Fernandez-
Salguero, P. (1996). Molecular basis
of the dihydropyrimidine dehydro-
genase deficiency and 5-fluorouracil
toxicity. J. Clin. Invest. 3, 610–615.
Yang, C. G., Ciccolini, J., Blesius,
A., Dahan, L., Bagarry-Liegey, D.,
Brunet, C., et al. (2011). DPD-based
adaptive dosing of 5-FU in patients
with head and neck cancer: impact
on treatment efficacy and toxicity.
Cancer Chemother. Pharmacol. 67,
49–56.
Yen, J. L., and McLeod, H. L. (2007).
Should DPD analysis be required
prior to prescribing fluoropy-
rimidines? Eur. J. Cancer 43,
1011–1016.
Yokota, H., Fernandez-Salguero, P.,
Furuya, H., Lin, K., McBride, O.
W., Podschun, B., et al. (1994).
cDNA cloning and chromosome
mapping of human dihydropyrim-
idine dehydrogenase, an enzyme
associated with 5-fluorouracil
toxicity and congenital thymine
uraciluria. J. Biol. Chem. 269,
23192–23196.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 30 August 2012; accepted: 19
December 2012; published online: 17
January 2013.
Citation: Borràs E, Dotor E, Arcusa
À, Gamundi MJ, Hernan I, de Sousa
Dias M, Mañé B, Agúndez JAG, Blanca
M and Carballo M (2013) High-
resolution melting analysis of the com-
mon c.1905+1G>A mutation causing
dihydropyrimidine dehydrogenase defi-
ciency and lethal 5-fluorouracil toxicity.
Front. Gene. 3:312. doi: 10.3389/fgene.
2012.00312
This article was submitted to
Frontiers in Pharmacogenetics and
Pharmacogenomics, a specialty of
Frontiers in Genetics.
Copyright © 2013 Borràs, Dotor,
Arcusa, Gamundi, Hernan, de Sousa
Dias, Mañé, Agúndez, Blanca and
Carballo. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics January 2013 | Volume 3 | Article 312 | 8
